CD8A and cancer: To put these findings into context, our group has reported higher discriminative capacities for other non-pathogen-specific biomarkers, such as the CD8+ T-cell count at month 1 (auROC of 0.739) or the total lymphocyte count at month 6 (auROC of 0.820) to predict opportunistic infection [25], Torque Teno virus (TTV DNAemia) at month 1 for predicting opportunistic infection and/or cancer (auROC of 0.704) [22], or serum sCD30 at month 1 for predicting bacterial infection (auROC of 0.846) [26].